Jason Litten

Company: Chimeric Therapeutics

Job title: Chief Medical Officer

Seminars:

Evaluating Donor-Derived Versus iPSC-Derived NK Therapies to Understand Advantages & Drawbacks of Each 1:05 pm

Dive into the source of NK cell therapies in this dynamic workshop, where we debate donor-derived versus iPSC-derived NK cells. Uncover the distinct advantages and challenges of each approach, from clinical effectiveness, editing efficiency to scalability. Gain the insights needed to make strategic decisions in sourcing NK cells. Comparing and contrasting different sources of NK cells to understand…Read more

day: Pre-Conference Workshop Day